10-Q: PDS Biotechnology Corp. Reports Second Quarter 2024 Financial Results and Provides Clinical Pipeline Update

PDS Biotechnology Corp. reports a net loss of $8.3 million for the second quarter of 2024, while highlighting progress in its clinical trials and pipeline development.

Summary

• PDS Biotechnology Corporation, a clinical-stage immunotherapy company, reported a net loss of $8.3 million for the three months ended June 30, 2024, and a net loss of $18.9 million for the six months ended June 30, 2024.
• The company's research and development expenses decreased to $4.5 million for the three months ended June 30, 2024, compared to $8.0 million for the same period in 2023.
• General and administrative expenses also decreased to $4.2 million for the three months ended June 30, 2024, from $4.7 million in the same period of 2023.
• As of June 30, 2024, PDS Biotechnology had $57.7 million in cash and cash equivalents.
• The company is developing a pipeline of immunotherapies, including Versamune, PDS01ADC, and Infectimune, targeting various cancers and infectious diseases.
• PDS Biotech is advancing clinical trials for its lead candidate, PDS0101, in combination with Keytruda for head and neck cancer, and is also exploring triple combination therapies.
• The company is also developing a universal flu vaccine, PDS0202, based on its Infectimune platform.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical trials and pipeline development, the company's financial losses and going concern issues raise significant concerns. The positive clinical data is encouraging, but the financial risks temper the overall sentiment.

Positives

• The company's cash position remains relatively strong at $57.7 million.
• The company is making progress in its clinical trials, particularly with the PDS0101 and Keytruda combination.
• The company is actively exploring triple combination therapies, which have shown promising results.
• The company is developing a universal flu vaccine, PDS0202, which has shown broad neutralization across multiple influenza strains in animals.
• The company has completed enrollment in the ICI nave arm of the VERSATILE-002 trial.

Negatives

• The company continues to experience net losses, with a loss of $8.3 million in Q2 2024.
• The company has no commercial products and is dependent on raising additional capital.
• The company's auditors have raised concerns about its ability to continue as a going concern.
• The company's loan agreement allows lenders to call the outstanding balance if minimum cash balances are not maintained.
• The company's research and development expenses, while decreased, are still substantial.

Risks

• The company's ability to continue as a going concern is uncertain due to ongoing losses and the need for additional financing.
• The company's clinical trials may not be successful, and regulatory approvals may not be obtained.
• The company faces competition from other biotechnology and pharmaceutical companies.
• The company's debt agreement contains covenants that could restrict its operations.
• The company's intellectual property may not be adequately protected.

Future Outlook

The company plans to continue funding its operations through existing cash, additional equity and/or debt financing, government funding programs, and potential partnerships. The company also plans to initiate a registrational study in first line treatment in HPV16-positive recurrent/metastatic HNSCC with the double combination of Versamune HPV + pembrolizumab.

Management Comments

• The company plans to execute its operating plan by obtaining additional capital, principally through issuance of equity through separate offerings or an at-the-market facility, issuance of debt, or by entering into collaborations, strategic alliances, or license agreements with third parties.
• The company may also enter into government funding programs and consider selectively partnering for clinical development and commercialization.

Industry Context

The company is operating in the competitive immunotherapy space, focusing on targeted therapies for cancer and infectious diseases. The company's approach of combining Versamune with PDS01ADC and immune checkpoint inhibitors is aligned with the industry trend of developing combination therapies to overcome resistance and improve patient outcomes. The development of a universal flu vaccine also addresses a significant unmet need in the infectious disease space.

Comparison to Industry Standards

• The reported median overall survival of approximately 20 months in the NCI-led Phase 2 trial for ICI-resistant patients is significantly higher than the historical median of 3-4 months with checkpoint inhibitors and 8.2 months with systemic therapy in similar patients.
• The 12-month overall survival rate of 87.1% in the VERSATILE-002 trial for ICI-naive patients is notably higher than the published results of 36-50% with approved ICIs used alone.
• The median progression-free survival of 10.4 months in the VERSATILE-002 trial is also higher than the published results of 2-3 months for approved ICIs when used as monotherapy in patients with similar PD-L1 levels.
• The confirmed overall response rate of 34% in the VERSATILE-002 trial for ICI-naive patients with CPS > 1 is higher than the less than 20% reported for comparable patients receiving treatment with ICIs.
• The company's approach of combining Versamune with PDS01ADC and immune checkpoint inhibitors is similar to other companies exploring combination therapies, such as Merck's Keytruda, but the specific combination and results are unique to PDS Biotech.

Stakeholder Impact

• Shareholders face the risk of dilution from potential equity raises and the uncertainty of the company's ability to continue as a going concern.
• Employees may be impacted by potential cost-cutting measures or restructuring if the company faces financial difficulties.
• Patients may benefit from the company's development of new immunotherapies, but the success of these therapies is not guaranteed.
• Creditors face the risk of non-payment if the company is unable to secure additional financing.

Next Steps

• The company plans to initiate a registrational study in first line treatment in HPV16-positive recurrent/metastatic HNSCC with the double combination of Versamune HPV + pembrolizumab.
• The company will continue to advance its clinical trials for PDS0101, PDS01ADC, and other candidates.
• The company will continue to evaluate the use of PDS01ADC in combination with other Versamune based clinical candidates.
• The company will continue to work with the NCI to determine the best pathway forward for the prioritized PDS01ADC studies.
• The company will continue to evaluate the next steps in the clinical development and funding for PDS0202.

Key Dates

Keywords

immunotherapy, clinical trials, oncology, infectious diseases, Versamune, PDS01ADC, Infectimune, head and neck cancer, universal flu vaccine, biotechnology